Orphazyme
Orphazyme is a Danish biotech-company focused on the development of novel therapies for lysosomal storage diseases. Orphazyme was founded in June 2009 by Thomas Kirkegaard Jensen (PhD, CEO), Martin Rahbek Kornum (Patent Attorney, Ch. of Board), Anders Hinsby (Partner, Bankinvest Biomedical Venture) & Marja Jäättelä (Prof., Head of Dep. of Apoptosis) via a pre-seed grant from the Novo Nordisk Foundation.